Solid Biosciences (SLDB) Projected to Post Earnings on Thursday

Solid Biosciences (NASDAQ:SLDB) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Solid Biosciences Stock Performance

Shares of SLDB opened at $6.31 on Thursday. Solid Biosciences has a 52-week low of $2.41 and a 52-week high of $7.37. The stock’s 50-day simple moving average is $5.98 and its 200 day simple moving average is $5.66. The stock has a market capitalization of $491.61 million, a price-to-earnings ratio of -2.53 and a beta of 2.67.

Wall Street Analyst Weigh In

SLDB has been the topic of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a report on Monday, February 9th. Chardan Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a research note on Tuesday, November 4th. JPMorgan Chase & Co. reduced their price target on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.70.

Insiders Place Their Bets

In other news, CEO Alexander Cumbo sold 80,258 shares of Solid Biosciences stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $516,861.52. Following the completion of the sale, the chief executive officer directly owned 270,931 shares of the company’s stock, valued at approximately $1,744,795.64. The trade was a 22.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO David T. Howton sold 37,771 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $243,245.24. Following the completion of the transaction, the chief operating officer owned 116,753 shares of the company’s stock, valued at $751,889.32. This trade represents a 24.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 620,596 shares of company stock worth $3,933,687. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Solid Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP boosted its holdings in shares of Solid Biosciences by 95.5% in the 4th quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after purchasing an additional 2,840,000 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Solid Biosciences by 505.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock worth $8,295,000 after buying an additional 1,421,968 shares during the last quarter. Bank of America Corp DE boosted its stake in Solid Biosciences by 2,150.4% in the second quarter. Bank of America Corp DE now owns 824,600 shares of the company’s stock worth $4,016,000 after buying an additional 787,957 shares in the last quarter. Woodline Partners LP purchased a new stake in Solid Biosciences in the first quarter worth approximately $2,338,000. Finally, Armistice Capital LLC grew its position in Solid Biosciences by 134.0% during the third quarter. Armistice Capital LLC now owns 936,000 shares of the company’s stock valued at $5,775,000 after acquiring an additional 536,000 shares during the last quarter. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.